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Nicotinamide phosphoribosyltransferase (Nampt) is the rate-limiting enzyme for NAD salvage and the abundance 
of Nampt has been shown to be altered in non-alcoholic fatty liver disease. It is, however, unknown how hepatic 
Nampt is regulated in response to accumulation of lipids in the liver of mice fed a high-fat diet (HFD). HFD mice 
gained more weight, stored more hepatic lipids and had an impaired glucose tolerance compared with control mice. 
NAD levels as well as Nampt mRNA expression, protein abundance and activity were significantly increased in HFD 
mice. Enhanced NAD levels were associated with deacetylation of p53 and Nfκb indicating increased activation of 
Sirt1. Despite impaired glucose tol- erance and increased hepatic lipid levels in HFD mice, NAD metabolism was 
significantly enhanced. Thus, improved NAD metabolism may be a compensatory mechanism to protect against 
negative impact of hepatic lipid accumulation. 
 
 
 
1. Introduction 
 
More than 30% of Western adult population is affected by non- 
alcoholic fatty liver diseases (NAFLD) with a rapidly increasing 
number in obese and diabetic people. NAFLD covers a wide range of 
conditions from simple steatosis caused by accumulation of tri- glycerides 
to non-alcoholic steatohepatitis (NASH) which is associated with 
inflammatory processes. NASH is a risk factor for fibrosis and cirrhosis 
which are associated with a significant liver-related mor- tality and a 
median survival of 6 years (Tarantino and Finelli, 2013). The pathological 
pathways leading to NASH are not yet fully un- derstood. Interestingly, 
specific sirtuins (Sirts) seem to affect the development of NAFLD by 
regulating processes like hepatic gluco- neogenesis, mitochondrial 
biogenesis and fatty acid synthesis. Liver- specific Sirt1 knockout mice 
develop hepatic steatosis and show impaired insulin signaling on a high-fat 
diet (HFD) (Purushotham et al., 2009), while global transgenic mice 
overexpressing Sirt1 are pro- tected against the negative effects of a HFD 
such as inflammation, impaired glucose tolerance and hepatic steatosis 
(Pfluger et al., 2008). 
Additionally, whole-body Sirt3 knockout mice show enhanced storage of 
hepatic triglycerides and insulin resistance (Hirschey et al., 2010) 
although liver-specific Sirt3 knockout mice do not display an overt 
phenotype (Fernandez-Marcos et al., 2012). 
Sirtuins are nicotinamide adenine dinucleotide (NAD) depen- dent 
in respect to their deacetylase activity. The key enzyme in the mammalian 
NAD salvage pathway starting from nicotinamide is nico- tinamide 
phosphoribosyltransferase (Nampt) which converts nicotinamide to 
nicotinamide mononucleotide (NMN), an interme- diate in NAD 
biosynthesis (Revollo et al., 2007a). Additionally, Nampt is secreted from 
adipocytes (Tanaka et al., 2007), hepatocytes (Garten et al., 2010), and 
leucocytes (Friebe et al., 2011). Nampt circulates in the blood where it acts 
as a NMN biosynthetic enzyme (Revollo et al., 2007b) and/or cytokine 
(Samal et al., 1994). Several human studies have investigated how Nampt 
protein levels in biopsies and blood are affected in individuals with 
steatosis and NASH, however, results are conflicting (Auguet et al., 
2013; Dahl et al., 2010; Kukla et al., 2010). 
It has been shown that rats fed a HFD develop fatty liver and hepatic insulin 
resistance already after 3 days of HFD feeding (Samuel et al., 2004). 
Moreover, another study in mice showed that hepatic insulin resistance is 
present already after 3 days on a HFD before insulin re- sistance develops in 
muscle and adipose tissue (Turner et al., 2013). Thus, hepatic insulin 
resistance develops very rapidly, but whether NAD metabolism is also 
affected in the early stages of the development of NAFLD is unknown. We 
hypothesize a link between the develop- ment of NAFLD and the ability to 
maintain NAD levels. To define the effect of lipid accumulation on hepatic 
NAD metabolism, we fed mice a HFD for 11 weeks and examined the 
effect on hepatic NAD me- tabolism. Despite hepatic lipid accumulation and 
impaired whole body glucose tolerance in mice fed a HFD, we found an 
improved hepatic NAD metabolism suggesting that this may be a 
compensatory mech- anism to protect against the negative impact of 
hepatic lipid accumulation on inflammation and apoptosis. 
 
 
 
2. Methods and procedures 
 
2.1. Mice and Ethical approval 
 
All experiments were approved by the Danish Animal Experi- mental 
Inspectorate and complied with the EU convention for protection of 
vertebra animals used for scientific purposes (Council of Europe 123, 
Strasbourg, France, 1985). Twenty-four male mice were obtained from 
Taconic when they were 10 weeks of age (C57BL/ 6Ntac, #DIO-B6). At 
the time of arrival in the laboratory, mice had been on a HFD (Research Diets 
Industry, D12492) or corresponding chow diet (Ctl) for 4 weeks. Mice were 
kept in a 12:12-h light:dark cycle and kept on the diet for additional 7 weeks. 
Water was given ad libitum. Mice were either single- (s) or group-housed (gr). To 
confirm that housing conditions (i.e., single- vs. group-housing) did not affect 
NAD metabolism, we measured Nampt protein abundance and NAD levels in a 
separate cohort of mice. In this cohort we applied 26 care- fully weight 
matched male mice (C57BL/6JBomTac) at 7 weeks of age. Upon arrival, the 
mice were acclimatized on a standard chow diet for 10 days before they were 
randomly assigned to the experimental groups and fed either a HFD (D12492) 
or a corresponding low fat diet (D12450J) for 11 weeks. The mice were either 
single-housed (5 mice per group per diet) or group-housed (8 mice per group 
per diet, 4 mice per cage) from the point of arrival to the day of termination. 
Housing conditions did not affect hepatic Nampt protein and NAD levels (Fig. 
S1A,B). After 11 weeks on their respective diets, mice were anesthetized 
(Pentobarbital, 100 mg/kg body weight) and livers were carefully dissected, 
frozen in liquid nitrogen, and stored at −80 °C until further analysis. Mice were 
all sacrificed at the same time point. 
 
2.2. Metabolic characterization 
 
Animals were weighed and body composition was assessed by MR scanning 
(EchoMRITM, USA). At the age of 14 and 15 weeks an oral glucose tolerance 
test (OGTT) and an insulin tolerance test (ITT) were performed, respectively. 
Both tests were performed after a 6-hour fast and blood glucose 
measurements were done from the tail vein. For the OGTT a bolus of glucose 
(25% glucose/saline solution, 2 g glucose/kg lean body mass) was delivered by 
oral gavage, and tail vein blood glucose was measured just before and at 20, 40, 
60, 90 and 120- minutes after the glucose bolus. The ITT was performed 
following 8 days of recovery after the OGTT. Insulin (100 U/ml) was diluted 
in gelofusine (B. Braun, Denmark) for a working solution of 0.333 U/ml, and 
administered by intraperitoneal injection (0.75 U/kg lean body mass). Blood 
glucose in the tail blood was measured before and at 15, 30, 45, 60, 90 and 
120-minutes after the injection. The mice were conscious, and placed in their 
cages during both tests. A week before collecting tissues, 200 μl of blood was 
drawn from the mandible into EDTA coated tubes, left to clot at room 
temperature for 30-minutes and spun down at 2000 × g at 4 °C for 10-minutes. 
Supernatants were transferred to clean tubes and stored at −80 °C. 
 
2.3. Triacylglycerol measurement of liver tissue 
 
The triacylglycerol (TAG) content of the liver tissue was quan- tified by 
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1H-high resolution magic-angle spinning–nuclear magnetic 
resonance spectroscopy. Five to fifteen milligrams of intact liver tissue was 
transferred into a 4 mm zirconia HR-MAS rotor with a volume of 15 μl. 
Additionally, 5 μl of a 100 μM solution of trisodium phos- phate was 
added as reference. The NMR spectra were recorded using a 600 MHz 
Bruker Avance III NMR spectrometer (Bruker, Rheinstetten, Germany). 
All measurements were conducted under MAS at a frequency of 9 kHz 
and a temperature of 25 °C. The water signal was suppressed by 
presaturation (1 mW power for 3 s). NMR spectra were excited by a π/2 
pulse of 4 μs duration. To allow for complete relaxation, the delay time 
between successive scans was 30 s. The amount of TAG was determined 
by comparing the inte- grals of the trisodium phosphate signal with the 
glycerol backbone signal at 4.29 ppm which is exclusively found in 
TAG. All spectra were corrected for baseline and phase distortions using 
Spinworks (University of Manitoba). Deconvolution of the signals was 
per- formed using an in-house written SciPy script. The peaks were fitted 
to a Voigt-Profile applying a constrained least-squares approach based 
on the L-BGFGS optimization algorithm (Zhu et al., 1997). The TAG 
content is expressed per gram liver tissue. 
 
 
2.4. Protein extraction, western blot analyses 
and immunoprecipitation 
 
Approximately 10 mg liver tissue was lysed in modified RIPA buffer 
as previously described (Schuster et al., 2014). Protein con- centration 
was determined using Pierce BCA protein assay (Thermo Scientific) and 
equal amounts of protein were separated by SDS– PAGE and 
transferred using a semi-dry transfer apparatus to nitrocellulose 
membranes. Next, membranes were blocked in 5% non- fat dry milk in 
TBS buffer containing 0.1% Tween 20. Applied antibodies are listed 
in Supplementary Table S1. Detection of pro- teins was carried out using 
Luminata Classico Western HRP Substrate (Merck Millipore) or 
Amersham ECL Prime Western Blotting De- tection Reagent (GE 
Healthcare). Gapdh immunoblotting was performed as a loading 
control. For immunoprecipitation livers were incubated with anti-acetyl 
lysine antibody conjugated to μMACS Protein A Micro Beads (Miltenyi 
Biotec) overnight and eluted with 1× SDS sample buffer. After 5 min 
heating, samples were analyzed by Western blotting with an anti-Srebp1 
antibody (H-160, Santa Cruz Biotechnology). 
 
 
2.5. Total RNA extraction and realtime qPCR 
 
Total RNA of liver tissue was extracted by TRIzol® Reagent (Life 
Technologies) according to manufacturer’s protocol. One micro- gram 
of total RNA was transcribed into cDNA by M-MLV Reverse 
Transcriptase (Invitrogen). Quantitative PCR analyses were per- 
formed using the qPCR Master Mix Plus Low ROX (Eurogentec) or 
Absolute qPCR SYBR Green Low ROX Mix (Thermo Scientific) and the 
Applied Biosystems 7500 Real Time PCR System. Primer se- quences 
are summarized in Supplementary Table S2. 
 
 
2.6. NAD measurement 
 
NAD was measured by EnzyChrom™ NAD+/NADH Assay Kit 
(E2ND-100, Biotrend) according to manufacturer’s protocol or 
reversed-phase HPLC using the Chromaster Purospher STAR RP- 18 
endcapped 3 μm Hibar RT 150-3 HPLC column (Merck). Ten 
milligrams of frozen liver tissue was sonicated in 100 μl 1 M per- chloric 
acid. After a 10-minute incubation period on ice samples were centrifuged 
and the supernatant was neutralized with 3 M potas- sium carbonate. 
After repeated centrifugation samples were loaded onto the column as 
previously described (Schuster et al., 2014). 
 
 
 
2.7. Nampt enzyme activity 
 
For determination of Nampt activity 10 mg of liver tissue was lysed 
in 100 μl Nampt enzyme assay buffer (0.1 M sodium phos- phate, pH 7.4) 
and protein concentration was determined using BCA protein assay. Thirty 
micrograms of protein was added to the re- action buffer and incubated 
at 37 °C for 1 h. Afterwards the assay using radiolabeled 14C-nicotinamide 
was performed as previously described (Garten et al., 2010). 
 
2.8. Serum Nampt measurement 
 
Nampt in mouse serum was measured by the Nampt (Visfatin/ PBEF) 
(mouse/rat) Dual ELISA Kit (AdipoGen Inc., Seoul, South Korea), according to 
manufacturer’s instructions. 
 
2.9. Statistical analysis 
 
Statistical analyses were performed with the open source lan- guage R 
in version 3.0.2 for triacylglycerol measurements or with GraphPad Prism® 
software (5.03) for all other statistical compari- sons. Significance levels 
were calculated by unpaired, two-tailed 
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t-tests or by repeated two-way ANOVA with subsequent Bonferroni post-
test where appropriate. For TAG measurement of liver tissue a two-
tailed Kruskal–Wallis test was conducted to determine sig- nificant 
differences between Ctl and HFD groups, because data were not normally 
distributed. Data represent mean ± SEM. p < 0.05 was considered 
significant. *p < 0.05; **p < 0.01; ***p < 0.001 compared to Ctl mice. 
 
3. Results 
 
3.1. Mice fed a high-fat diet have impaired glucose tolerance 
and increased hepatic lipid content while markers for fibrosis 
and inflammation are not altered 
 
To determine how a HFD affects hepatic NAD metabolism, a cohort 
of mice were put on a HFD (60% of total energy from fat) or Ctl diet for 11 
weeks at 6 weeks of age. After 11 weeks on HFD, mice were significantly 
heavier (39.0 ± 4.2 g vs. 29.9 ± 2.5 g) (Fig. 1A) and had significantly 
increased amounts of  body fat (13.3 ± 1.1   vs. 
3.3 ± 0.6 g) (Fig. 1B) compared to Ctl mice. Lean body mass was sig- 
nificantly higher in Ctl vs. HFD mice (25.5 ± 0.5 vs. 23.0 ± 0.3 g) 
(Fig. 1C). HFD mice showed a significantly impaired oral glucose 
 
 
 
 
Fig. 1. Mice fed a high fat diet have impaired glucose tolerance and increased hepatic lipid content while markers for fibrosis and inflammation are not altered. Mice fed a high fat diet (HFD) 
for 11 weeks gained weight (A) and fat body mass (B) while lean body mass (C) was decreased compared to controls (Ctl). The HFD mice showed an impaired oral glucose tolerance (D) 
and insulin tolerance (E) compared to Ctl. Livers of HFD mice showed higher levels of triglycerides (F) but no indication for macrophage infiltration as measured by CD68 expression. α-Sma 
was significantly down regulated in livers of mice fed a HFD while fibrinogen and collagen I expression as markers for fibrosis stayed stable. mRNA expressions of markers for inflammation 
(TNFα and, Il-6) were unchanged in both groups (G). Data are shown as means ± SEM. n.s., not significant, 
*p < 0.05, **p < 0.01 and ***p < 0.001 compared to Ctl mice. 
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tolerance (p < 0.001). Significant differences in fasting blood glucose as 
well as at 20, 40, 60 and 90 min were found between the Ctl and HFD 
groups (Fig. 1D). In the insulin tolerance test a main effect of diet (p = 
0.0018) and a borderline significant interaction effect were observed (p = 
0.055; observed power, P = 0.78) (Fig. 1E). Hepatic TAG content was 2.1-
fold increased compared to Ctl mice (93.2 ± 12.6 vs. 44.1 ± 3.8 mg/g 
tissue) (Fig. 1F). To further evaluate the state of NAFLD we measured a 
marker for macrophage infiltration, CD68, which was not different 
between both groups. α-smooth muscle actin (α-Sma) was decreased in 
HFD mice while other markers for fibro- sis (fibrinogen, collagen I) were 
not different. Interleukin-6 (Il-6) and tumor necrosis factor alpha (Tnfα) 
as markers for inflammation were not changed in HFD mice (Fig. 1G). 
mRNA expression of the cytokines chemokine (C-X-C motif) ligand 16 
(Cxcl16), monocyte chemotactic protein 1 (Mcp-I) and transforming 
growth factor β (Tgfβ) were not different in the livers of mice fed a HFD 
compared to Ctl. mRNA ex- pression of the co receptor of the T cell 
receptor CD8 and the fatty acid translocase CD36 were not changed in the 
livers of the HFD mice (Supplementary Fig. S2A). Carnitine 
palmitoyltransferase (Cpt)-Iα and- II are two mitochondrial enzymes 
which are important for β oxidation of long-chain fatty acids. Both 
stayed stable in mice fed a HFD (Supplementary Fig. S2B). Furthermore, 
we detected less en- doplasmic reticulum stress in livers of HFD mice 
indicated by lower levels of phosphorylated eIF2α compared to Ctl mice 
(Supplementary Fig. S2C). 
 
3.2. High-fat diet up regulates hepatic Nampt mRNA expression, 
protein levels, activity, and NAD levels 
 
Nampt levels have been shown to be either up or down regu- lated in 
different studies on insulin resistance and glucose intolerance (Friebe et al., 
2011; Goktas et al., 2013; Olszanecka-Glinianowicz 
et al., 2014). Interestingly, both mRNA and protein levels of Nampt were 
increased in HFD mice compared with Ctl mice by 1.9-fold and 1.7-fold, 
respectively (Fig. 2A,B). This was in line with a significant 1.5-fold increase 
in Nampt enzyme activity (41.4 ± 4.2 vs. 65.8 ± 5.8 cpm/μg protein × h) in 
the HFD fed mice (Fig. 2C). Because Nampt is the key regulator of the 
mammalian NAD salvage pathway we measured hepatic NAD levels and 
found that NAD was signifi- cantly increased by 1.6-fold in the HFD mice 
compared to Ctl mice (4.2 ± 0.3 vs. 6.7 ± 0.5 nmol/mg protein) (Fig. 2D). 
Since hepato- cytes are able to secrete Nampt (Garten et al., 2010), we 
measured Nampt in mouse serum samples from the mice. However, no 
dif- ferences between HFD and Ctl group were observed (19.8 ± 4.9 vs. 
14.6 ± 1.3 ng/ml) (Fig. 2E). 
 
3.3. Acetylation of Nfκb and p53 is decreased while Sirt1 protein is 
increased in HFD mice 
 
Since NAD is a required substrate for deacetylases and since total hepatic 
acetylation of the HFD mice was down regulated (Supplementary Fig. 
S3A), we measured the acetylation state of Nfκb (ac-Nfκb) and p53 (ac-
p53), which are involved in the regulation of inflammation and apoptosis, 
respectively (Yeung et al., 2004). Total NfκB protein was up regulated in 
livers of HFD mice compared to Ctl mice while the acetylation of NfκB 
stayed stable resulting in 2.1- fold less acetylated NfκB (Fig. 3A). We 
found that total and phosphorylated p53 protein was  not  changed  
(Supplementary Fig. S2D), while acetylated p53 was significantly 
reduced by 1.8- fold (Fig. 3A), implicating that p53 was less active in 
murine livers of HFD mice compared to Ctl mice. In support of this finding, 
Bax, a downstream target of p53, was decreased by 1.6-fold (Fig. 3A). As 
NAD levels were up regulated resulting in lower levels of acety- lated 
p53 and NfκB, we further investigated protein and mRNA levels 
 
 
 
 
Fig. 2. HFD up regulates hepatic Nampt expression and activity as well as NAD levels. After a HFD for 11 weeks murine livers showed an increased Nampt mRNA (A) and protein amount (B) 
measured by qPCR or western blot analyses, respectively, compared to Ctl mice. Nampt activity (C) and intracellular NAD levels (D) measured by HPLC were enhanced. Serum Nampt levels 
were unchanged between both groups (E). Data are shown as means ± SEM (n = 12). One representative Western Blot is shown. **p < 0.01 and ***p < 0.001 compared to Ctl mice. 
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Fig. 3. Acetylation state of Nfκb and p53 are down regulated in HFD mice which is associated with increased Sirt1 protein expression. The acetylation status of Nfκb (ac-Nfκb), acetylated 
p53 (ac-p53) and total Bax protein were decreased in livers of mice fed a HFD compared to Ctl mice as shown by densitometric analysis of Western blots (A). Sirt1 and Sirt3 mRNA (B) 
and protein levels (C) in liver tissues were measured by qPCR and Western blot analyses, respectively. Hepatic Sirt1 protein was up regu- lated in mice fed a HFD for 11 weeks compared to Ctl 
mice. Data are shown as means ± SEM (n = 12). One representative Western blot is shown. Acetylated protein is normalized to the corresponding total protein. Gapdh is used as loading control. 
n.s., not significant, *p < 0.05, **p < 0.01 and ***p < 0.001 compared to Ctl mice. 
 
of Sirt1 and Sirt3 which are proteins known to be regulated during NAFLD 
development (Hirschey et al., 2010; Purushotham et al., 2009). No differences 
in Sirt1 and Sirt3 mRNA levels were detected between groups (Fig. 3B). 
However, Sirt1 protein was significantly in- creased by 1.4-fold in the 
HFD group compared to Ctl while Sirt3 protein amount stayed stable (Fig. 
3C). 
 
3.4. Expression of sirtuin downstream targets is altered in 
mice fed a HFD 
 
The expression of further sirtuin targets that are associated with the 
pathogenesis of NAFLD was analyzed. Mitochondrial uncoupling protein 
2 (Ucp2) was significantly reduced by 1.4-fold in HFD mice 
compared to Ctl mice while peroxisome proliferator-activated recep- tor 
gamma coactivator 1 α (Pgc-1α) and mitochondrial superoxide 
dismutase (MnSOD), markers of the mitochondrial biogenesis, were 
unchanged (Fig. 4A). Sirt3 deacetylates MnSOD at K122 resulting in 
increased MnSOD activity (Tao et al., 2010). Using an antibody tar- geting 
acetylated MnSOD K122 (kindly provided by Prof. David Gius, North 
Westwestern University) we measured the acetylation state of MnSOD 
and found no differences on total protein and acetyla- tion level 
(Supplementary Fig. S3B). Sirt1 is a transcriptional regulator of sterol 
regulatory element-binding protein 1 (Srebp-1c) (Defour et al., 2012), a 
key regulator of de novo lipogenesis in the liver. Srebp-1c was enhanced 
by 1.9-fold while its downstream targets fatty acid synthase (Fas), 
stearoyl-CoA-desaturase 1 (Scd1) and acetyl-coA- 
 
 
 
 
Fig. 4. Sirt1 downstream targets were altered in mice fed a HFD. HFD mice showed a reduced expression of Ucp2 while Pgc1α and MnSOD were unchanged (A) as ana- lyzed by qPCR. 
Srebp-1c mRNA expression was up regulated while Fas, Acc and Scd1 mRNA expression was declined compared to Ctl mice (B). G6pc and Pepck were both decreased in mice fed a HFD 
(C). n.s., not significant, *p < 0.05, **p < 0.01 and ***p < 0.001 compared to Ctl mice. 
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carboxylase (Acc) were significantly declined (Fig. 4B). Acetylation of 
Srebp-1 was not significantly different in both groups 
(Supplementary Fig. S3C). Glucose-6-phosphatase (G6pc) and phos- 
phoenolpyruvate carboxykinase (Pepck), key enzymes of 
gluconeogenesis, were both downregulated by 1.8-fold and 2.2- fold, 
respectively, in the livers of the HFD mice compared to control chow (Fig. 
4C). 
 
4. Discussion 
 
The impact of hepatic lipid accumulation on NAD metabolism in the 
liver is incompletely known. To this end we evaluated the effect of a HFD 
intervention in mice on the hepatic NAD salvage pathway. The HFD 
mouse model employed in this study represents the human phenotype 
of hepatosteatosis with increased hepatic TAG accumulation, but 
without any indications of macrophage infiltra- tion or fibrosis. Our data 
are also in accordance with data from other studies using HFD mice 
(Takahashi et al., 2012). Mice on HFD had impaired glucose tolerance, 
higher fasting blood glucose levels as well as a borderline significant 
reduction in insulin tolerance com- pared to mice on normal chow. 
Collectively, this indicates that HFD- 
fed mice had decreased peripheral insulin sensitivity. 
Interestingly, we found an up regulation in the capacity for NAD salvage 
in the livers of the HFD-fed mice, indicated by up regulated expression and 
activity of the NAD salvage enzyme Nampt and in- creased NAD levels. 
The enhanced NAD salvage we observed could be a prerequisite for the 
up regulation of mitochondrial metabo- lism as an adaptive mechanism 
in response to chronic fat overload as described in other studies (Koliaki 
and Roden, 2013), since an increase in β-oxidation and tricarboxylic acid 
cycle flux would require increased levels of NAD. In general, it has been 
shown that mice fed a HFD exhibit decreased hepatic Nampt levels, while 
an up reg- ulation of Nampt ameliorated the negative impact of HFD in the 
liver and augmented glucose tolerance (Tao et al., 2011; Yoshino et al., 
2011). In contrast, and in accordance with our study, another study showed 
an up regulation of Nampt mRNA in a rat model of NAFLD (Chang et al., 
2014). Reasons for the discrepant results of animal studies could be the 
composition and duration of the HFD as well as mouse strain-dependent 
differences (Heiker et al., 2014). Con- flicting data about the role of 
hepatic Nampt in humans have been reported. In obese women hepatic 
NAMPT mRNA levels in the liver were shown to be higher compared to 
lean women and were even further increased in obese women with NAFLD, 
which is in line with our data (Auguet et al., 2013). A different human study 
found higher NAMPT mRNA expression level in fibrotic livers (Kukla et al., 
2010). Opposite, it has also been reported that patients with NAFLD showed 
lower levels of NAMPT mRNA expression in the liver (Dahl et al., 2010). The 
reason for the discrepancies between these studies is unknown but it could 
be due to variations in the progression of NAFLD. 
As a result of increased NAD levels an enhanced Sirt1 deacetylase 
activity in the livers of the HFD-fed mice was detected as shown by less 
acetylation of Nf-κb on lysine 310 (Yeung et al., 2004) and p53 on lysine 
382 (Vaziri et al., 2001). By deacetylating p53 at lysine 382 Sirt1 is able 
to repress the activity of p53, a master regulator of apoptosis and cell 
cycle progression (Vaziri et al., 2001). In liver biopsies from subjects 
with NAFLD Sirt1 was shown to be de- creased leading to increased 
acetylation of p53 compared to Ctl patients (Castro et al., 2013). The lower 
activity of p53 in the present study was confirmed by the observed down 
regulation of the p53 downstream target Bax in HFD murine livers (Rozan 
and El-Deiry, 2007). Nf-κb is a critical factor in the innate immunity 
response and is directly affected by Sirt1 which deacetylates the ReIA/p65 
com- ponent of Nf-κb leading to a down regulation of its activity and 
degradation (Yeung et al., 2004). A global over expression of Sirt1 in 
mice subjected to HFD has been shown to improve hepatic in- 
flammation by decreasing activity of Nf-κb (Pfluger et al., 2008). 
The increased Sirt1 activity in HFD-fed mice was confirmed by 
detecting a down regulation of Ucp2. This mitochondrial inner 
membrane protein negatively regulates reactive oxygen species (ROS) 
production and has been demonstrated by others to be up regulated in 
NAFLD (Kohjima et al., 2007). Sirt1 is known to regulate Ucp2 by binding 
to its promoter resulting in down regulation of Ucp2 mRNA expression 
(Bordone et al., 2006). Our data indicate that a higher ac- tivity of Sirt1 led 
to a down regulation of Ucp2 in HFD mouse livers suggesting that oxidative 
stress was not present in our murine model at the analysed time point. The 
absence of oxidative stress was sup- ported by the fact that MnSod, a key 
ROS scavenging enzyme (Tao et al., 2010), was not different on mRNA level 
as well as on total and acetylated protein level in our murine model. 
Srebp-1c can be inhibited by Sirt1 and is a key regulator of de novo 
lipogenesis, which plays a crucial role in the pathogenesis of NAFLD. 
Srebp-1c is mainly activated by saturated fatty acids and elevated insulin 
levels (Aragno et al., 2009; Haas et al., 2012). In line with these studies, we 
found higher Srebp-1c mRNA expression in livers of HFD-fed mice. 
Despite increased TAG accumulation in the liver of HFD-fed mice it might 
however be reasonably assumed that Srebp-1c was less active due to 
deacetylation by Sirt1 (Ponugoti et al., 2010), emphasized by lower mRNA 
levels of its downstream targets Fas, Acc and Scd1. However, in our study 
acetylation of Srebp-1 was not significantly altered in mice fed a HFD 
compared to Ctl. Tran- scriptional activity of Srebp-1c is also regulated by 
phosphorylation due to activation of AMPK which suppresses Srebp-1c 
cleavage and nuclear translocation in insulin resistant LDL receptor deficient 
mice and therefore represses de novo lipogenesis (Li et al., 2011). Inter- 
estingly we could also find a decreased expression of the two key enzymes 
of gluconeogenesis G6pc and Pepck which might be due to higher activity 
of Sirt1 leading to an increased phosphorylation (Wang et al., 2011) and 
decreased acetylation of FoxO1 (Motta et al., 2004) and thus inhibiting the 
transcription of G6pc and Pepck. 
Besides elevated Sirt1 activity, we found increased hepatic Sirt1 protein 
expression in HFD-fed mice. There are several contradic- tory studies on 
Sirt1 expression in the livers of NAFLD animal models. Rats on a HFD for 3 
months were reported to develop hepatic ste- atosis accompanied by 
decreased Sirt1 protein levels (Deng et al., 2007), while in other studies 
Sirt1 over expression was found to be protective against the negative impact 
of a HFD (Pfluger et al., 2008; Purushotham et al., 2009). In contrast, it has 
been shown that liver- specific Sirt1 knockout mice stored less fat in white 
adipose tissue and liver under HFD conditions (Chen et al., 2008). In 
addition, liver- specific Sirt1 knockout mice were more glucose tolerant 
and had lower levels of blood glucose and insulin than wild type controls 
(Chen et al., 2008). Taken together, the association between Sirt1 
protein and activity levels, hepatic lipid accumulation and result- ing 
metabolic disturbances is not yet clarified and may be associated with 
disease progression and inflammatory conditions. 
In summary, we detected an up regulation of the NAD salvage 
pathway and concomitantly increased Sirt1 deacetylase activity in the 
livers of mice fed a HFD diet for 11 weeks. One could suppose that up 
regulation of Nampt activity and NAD levels is an early com- pensatory 
mechanism to protect the liver against the negative consequences of 
lipid accumulation. The negative impact of an 11- week HFD was being 
counteracted via higher Nampt and Sirt1 activities. It is possible that a 
more prolonged HFD exposure would lead to impaired regulation of hepatic 
Nampt and NAD levels, thus contributing to the development of 
steatohepatitis. 
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